SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-19-000026
Filing Date
2019-05-02
Accepted
2019-05-02 16:57:42
Documents
42
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20190331x10q.htm 10-Q 667613
2 EX-31.1 sava-20190331xex31_1.htm EX-31.1 25499
3 EX-31.2 sava-20190331xex31_2.htm EX-31.2 25198
4 EX-32.1 sava-20190331xex32_1.htm EX-32.1 20241
  Complete submission text file 0001069530-19-000026.txt   2476196

Data Files

Seq Description Document Type Size
5 EX-101.INS sava-20190331.xml EX-101.INS 439401
6 EX-101.SCH sava-20190331.xsd EX-101.SCH 21899
7 EX-101.CAL sava-20190331_cal.xml EX-101.CAL 23130
8 EX-101.DEF sava-20190331_def.xml EX-101.DEF 54019
9 EX-101.LAB sava-20190331_lab.xml EX-101.LAB 155912
10 EX-101.PRE sava-20190331_pre.xml EX-101.PRE 136800
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 19792767
SIC: 2834 Pharmaceutical Preparations